Int J Clin Pharmacol Ther. 2012 Aug;50(8):557-65. doi: 10.5414/CP201709.

The pharmacokinetics of letrozole: association with key body mass metrics.

Jin SJ, Jung JA, Cho SH, Kim UJ, Choe S, Ghim JL, Noh YH, Park HJ, Kim JC, Jung JA, Lim HS, Bae KS.

Abstract

PURPOSE:

To characterize the pharmacokinetics (PK) of letrozole by noncompartmental and mixed effect modeling analysis with the exploration of effect of body compositions on the PK.

METHODS:

The PK data of 52 normal healthy male subjects with intensive PK sampling from two separate studies were included in this analysis. Subjects were given a single oral administration of 2.5 mg letrozole (Femara®), an antiestrogenic aromatase inhibitor used to treat breast cancer. Letrozole concentrations were measured using validated high-performance liquid chromatography with tandem massspectrometry. PK analysis was performed using NONMEM® 7.2 with first-order conditional estimation with interaction method. The association of body composition (body mass index, soft lean mass, fat free mass, body fat mass), CYP2A6 genotype (*1/*1, *1/*4), and CYP3A5 genotype (*1/*1, *1/*3, *3/*3) with the PK of letrozole were tested.

RESULTS:

A two-compartment model with mixed first and zero order absorption and first order elimination best described the letrozoleconcentration-time profile. Body weight and body fat mass were significant covariates for central volume of distribution and peripheral volume of distribution (Vp), respectively. In another model built using more readily available body composition measures, body mass index was also a significant covariate of Vp. However, no significant association was shown between CYP2A6 and CYP3A5 genetic polymorphism and the PK of letrozole in this study.

CONCLUSION:

Our results indicate that body weight, body fat mass, body mass index are associated with the volume of distribution of letrozole. This study provides an initial step toward the development of individualized letrozole therapy based on body composition.

PMID:

22735458

DOI:

10.5414/CP201709